Compared to other cancers, the reprogramming of glucose metabolism in PDAC exhibits highly unique adaptive strategies, features that directly derive from its oncogenic driver mutations (e.g., Kras) and the extremely harsh tumor microenvironment. This evidence concerns the gene KRAS and neoplasm.